A Bayesian design for phase I cancer therapeutic vaccine trials
From MaRDI portal
(Redirected from Publication:6625928)
A Bayesian design for phase I cancer therapeutic vaccine trials (scientific article; zbMATH DE number 7933150)
A Bayesian design for phase I cancer therapeutic vaccine trials (scientific article; zbMATH DE number 7933150)
Cites work
- A Bayesian adaptive dose-finding algorithm for balancing individual- and population-level ethics in phase I clinical trials
- A Bayesian phase I/II trial design for immunotherapy
- A Strategy for Dose-Finding and Safety Monitoring Based on Efficacy and Adverse Outcomes in Phase I/II Clinical Trials
- Bayesian data analysis.
- Bayesian designs for phase I--II clinical trials
- Bayesian Dose-Finding in Phase I/II Clinical Trials Using Toxicity and Efficacy Odds Ratios
- Bayesian Estimation Methods for 2 × 2 Contingency Tables Using Mixtures of Dirichlet Distributions
- Bayesian Model Averaging Continual Reassessment Method in Phase I Clinical Trials
- Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
- Dose finding with escalation with overdose control (EWOC) in cancer clinical trials
- Dose-Finding Based on Efficacy-Toxicity Trade-Offs
- Dose-finding designs for HIV studies
- Statistical properties of the traditional algorithm-based designs for phase I cancer clinical trials
- Utility-Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials
Cited in
(2)
This page was built for publication: A Bayesian design for phase I cancer therapeutic vaccine trials
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q6625928)
